Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

Launched by MEDICAL UNIVERSITY OF VIENNA · Feb 20, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how patients with uveal melanoma, a type of eye cancer, respond to a specific treatment called hypofractionated stereotactic photon radiotherapy. The main goal is to see if this treatment causes any problems with vision, specifically conditions known as retinopathy and opticopathy, one year after the treatment. The study will track patients' eye health through various imaging tests at several points: before treatment and then again at 3, 6, 9, and 12 months afterward.

To participate in this study, you would need to be a patient diagnosed with uveal melanoma who is planning to receive this radiation therapy. However, if you are unwilling to take part or have serious issues with your eye’s clarity that prevent clear imaging, you may not be eligible. If you join the study, you can expect to have your eyes regularly checked to monitor any changes in your vision after the treatment. This research is important as it helps doctors understand the long-term effects of this specific radiation therapy on vision, which can ultimately improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed uveal melanoma, who will be treated with hypofractionated stereotactic photon radiotherapy as part of clinical routine.
• Exclusion Criteria:
• • unwillingness to participate in the study
• • severe media opacity